Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
38.50
-0.41 (-1.05%)
Dec 5, 2025, 4:00 PM EST - Market closed
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 46.4, with a low estimate of 26 and a high estimate of 56. The average target predicts an increase of 20.52% from the current stock price of 38.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $52 → $56 | Strong Buy | Maintains | $52 → $56 | +45.45% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $55 | Buy | Maintains | $50 → $55 | +42.86% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $42 → $52 | Strong Buy | Maintains | $42 → $52 | +35.06% | Oct 30, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $50 | Buy | Maintains | $26 → $50 | +29.87% | Sep 11, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $32 → $52 | Strong Buy | Maintains | $32 → $52 | +35.06% | Sep 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.71
from -3.66
EPS Next Year
-2.40
from -2.71
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.43 | -1.83 | ||||
| Avg | -2.71 | -2.40 | ||||
| Low | -3.37 | -3.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.